The role of mental health in obesity management
DOI:
https://doi.org/10.7196/SAMJ.2025.v115i9b.3697Keywords:
Mental Health, Obesity, Guideline, South AfricaAbstract
RECOMMENDATIONS
1. We recommend regular monitoring of weight, glucose and lipid profile in people with a mental health diagnosis who are taking medications associated with weight gain (Level 3, Grade C).
2. Healthcare providers can consider both efficacy and effects on body weight when choosing psychiatric medications (Level 2a, Grade B).
3. Metformin and psychological treatment, such as CBT, should be considered for prevention of weight gain in people with severe mental illness who are treated with antipsychotic medications associated with weight gain (Level 1a, Grade A).
References
1. Morin AK. Off-label use of atypical antipsychotic agents for treatment of insomnia. Ment Health Clin 2014;4(2):65-72. https://doi.org/10.9740/mhc.n190091
2. LudwickJJ,OosthuizenPP.Screeningforandmonitoringofcardio-metabolicriskfactorsinoutpatients with severe mental illness in a primary care setting. Afr J Psychiatry (Johannesbg) 2009;12(4):287-292. https://doi.org/10.4314/ajpsy.v12i4.49047
3. Arterburn D, Sofer T, Boudreau DM, et al. Long-term weight change after initiating second-generation antidepressants. J Clin Med 2016;5(4):48. https://doi.org/10.3390/jcm5040048
4. Correll CU, Detraux J, de Lepeleire J, de Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015;14(2):119-136. https://doi.org/10.1002/wps.20204
5. Thompson A, Hetrick SE, Alvarez-Jimenez M, et al. Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis. Aust N Z J Psychiatry 2011;45(9):740-748. https://doi.org/10.3109/00048674.2011.595370
6. Patten SB, Williams JV, Lavorato DH, Khaled S, Bulloch AGM. Weight gain in relation to major depression and antidepressant medication use. J Affect Disord 2011;134(1-3):288-293. https://doi. org/10.1016/j.jad.2011.06.027
7. Chouinard VA, Pingali SM, Chouinard G, et al. Factors associated with overweight and obesity in schizophrenia, schizoaffective and bipolar disorders. Psychiatry Res 2016;237:304-310. https://doi. org/10.1016/j.psychres.2016.01.024
8. Fjukstad KK, Engum A, Lydersen S, et al. Metabolic abnormalities related to treatment with selective serotonin reuptake inhibitors in patients with schizophrenia or bipolar disorder. J Clin Psychopharmacol 2016;36(6):615-620. https://doi.org/10.1097/JCP.0000000000000582
9. Smits JA, Rosenfield D, Mather AA, Tart CD, Henriksen C, Sareen J. Psychotropic medication use mediates the relationship between mood and anxiety disorders and obesity: Findings from a nationally representative sample. J Psychiatr Res 2010;44(15):1010-1016. https://doi.org/10.1016/j. jpsychires.2010.04.007
10. Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: A meta-analysis. PLoS ONE 2014;9(4):e94112. https://doi.org/10.1371/journal.pone.0094112
11. Strassnig M, Kotov R, Cornaccio D, Fochtmann L, Harvey PD, Bromet EJ. Twenty-year progression of body mass index in a county-wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis. Bipolar Disord 2017;19(5):336-343. https://doi.org/10.1111/bdi.12505
12. Arterburn D, Wood GC, Theis MK, et al. Antipsychotic medications and extreme weight gain in two health systems. Obes Res Clin Pract 2016;10(4):408-423. https://doi.org/10.1016/j.orcp.2015.08.012
13. VandenbergheF,Gholam-RezaeeM,Saigi-MorguiN,etal.Importanceofearlyweightchangestopredict
long-term weight gain during psychotropic drug treatment. J Clin Psychiatry 2015;76(11):e1417-e1423.
https://doi.org/10.4088/JCP.14m09358
14. Correll CU, Robinson DG, Schooler NR, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: Baseline results from the RAISE-ETP study. JAMA Psychiatry 2014;71(12):1350-1363. https://doi.org/10.1001/jamapsychiatry.2014.1314
15. Boudreau DM, Arterburn D, Bogart A, et al. Influence of body mass index on the choice of therapy for depression and follow-up care. Obesity (Silver Spring) 2013;21(3):E303-E313. https://doi.org/10.1002/ oby.20048
16. Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: A systematic review and meta-analysis. Schizophr Bull 2014;40(6):1385-1403. https://doi.org/10.1093/schbul/sbu030
17. Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: Meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 2015;35(5):499-509. https://doi.org/10.1097/JCP.0000000000000392
18. Taylor VH, McIntyre RS, Remington G, Levitan RD, Stonehocker B, Sharma AM. Beyond pharmacotherapy: Understanding the links between obesity and chronic mental illness. Can J Psychiatry 2012;57(1):5-12. https://doi.org/10.1177/070674371205700103
19. CalkinC,vandeVeldeC,RuzickovaM,etal.Canbodymassindexhelppredictoutcomeinpatientswith bipolar disorder? Bipolar Disord 2009;11(6):650-656. https://doi.org/10.1111/j.1399-5618.2009.00730.x
20. Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry 2007;62(4):321-326. https://doi.org/10.1016/j.biopsych.2006.10.001
21. Pearl RL, Puhl RM. Weight bias internalization and health: A systematic review. Obes Rev 2018;19(8):1141-1163. https://doi.org/10.1111/obr.12701
22. Mulligan K, McBain H, Lamontagne-Godwin F, et al. Barriers to effective diabetes management – a survey of people with severe mental illness. BMC Psychiatry 2018;18(1):165. https://doi.org/10.1186/ s12888-018-1744-5
23. Afzal M, Siddiqi N, Ahmad B, et al. Prevalence of overweight and obesity in people with severe mental illness: Systematic review and meta-analysis. Front Endocrinol (Lausanne) 2021;12:769309. https://doi. org/10.3389/fendo.2021.769309
24. Mchiza ZJ-R, Parker W-A, Hossin MZ, et al. Social and psychological predictors of body mass index among South Africans 15 years and older: SANHANES-1. Int J Environ Res Public Health 2019;16(20):3919. https://doi.org/10.3390/ijerph16203919
25. Saloojee S, Burns JK, Motala AA. Metabolic syndrome in South African patients with severe mental illness: Prevalence and associated risk factors. PLoS ONE 2016;11(2):e0149209. https://doi.org/10.1371/ journal.pone.0149209
26. Saloojee S, Burns JK, Motala AA. Very low rates of screening for metabolic syndrome among patients with severe mental illness in Durban, South Africa. BMC Psychiatry 2014;14:228. https://doi. org/10.1186/s12888-014-0228-5
27. Goldstein BI, Liu SM, Schaffer A, Sala R, Blanco C. Obesity and the three-year longitudinal course of bipolar disorder. Bipolar Disord 2013;15(3):284-293. https://doi.org/10.1111/bdi.12035
28. Avila C, Holloway AC, Hahn MK, et al. An overview of links between obesity and mental health. Curr Obes Rep 2015;4(3):303-310. https://doi.org/10.1007/s13679-015-0164-9
29. Kivimaki M, Batty GD, Singh-Manoux A, et al. Association between common mental disorder and obesity over the adult life course. Br J Psychiatry 2009;195(2):149-155. https://doi.org/10.1192/bjp. bp.108.057299
30. Hasnain M, Vieweg WV, Hollett B. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: A review for primary care physicians. Postgrad Med 2012;124(4):154- 167. https://doi.org/10.3810/pgm.2012.07.2577
31. BradshawT,MairsH.Obesityandseriousmentalillhealth:Acriticalreviewoftheliterature.Healthcare (Basel) 2014;2(2):166-182. https://doi.org/10.3390/healthcare2020166
32. Hensel JM, Taylor VH, Fung K, Vigod SN. Rates of mental illness and addiction among high- cost users of medical services in Ontario. Can J Psychiatry 2016;61(6):358-366. https://doi. org/10.1177/0706743716644764
33. Wong MM, Chen EYH, Lui SSY, Tso S. Medication adherence and subjective weight perception in patients with first-episode psychotic disorder. Clin Schizophr Relat Psychoses 2011;5(3):135-141. https:// doi.org/10.3371/CSRP.5.3.3
34. ThorpeJ,SaeedS,MoodieEE,KleinMB;CanadianCo-infectionCohortStudy(CTN222).Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS 2011;25(7):967-975. https://doi.org/10.1097/QAD.0b013e3283455e4b
35. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. Lancet Psychiatry 2020;7(1):64-77. https://doi.org/10.1016/S2215-0366(19)30416-X
36. Pringsheim T, Gardner DM. Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: A descriptive study. CMAJ Open 2014;2(4): E225-E232. https://doi.org/10.9778/cmajo.20140009
37. Maglione M, Maher AR, Hu J, et al. Off-label use of atypical antipsychotics: An update. Rockville, Md: Agency for Healthcare Research and Quality, 2011. Sep. Report No.: 11-EHC087-EF. PMID: 22132426.
38. Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended-release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: A long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol 2011;26(1):11-
24. https://doi.org/10.1097/YIC.0b013e32833e34d9
39. RayWA,ChungCP,MurrayKT,HallK,SteinCM.Atypicalantipsychoticdrugsandtheriskofsudden
cardiac death. N Engl J Med 2009;360(3):225-235. https://doi.org/10.1056/NEJMoa0806994
40. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007;146(11):775-786. https://doi.org/10.7326/0003-4819-146-11- 200706050-00006
41. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14(3):191-210. https://doi.org/10.1097/01.JGP.0000200589.01396.6d
42. Tek C. Naltrexone HCl/bupropion HCl for chronic weight management in obese adults: Patient selection and perspectives. Patient Prefer Adherence 2016;10:751-759. https://doi.org/10.2147/PPA.S84778
43. Marteene W, Winckel K, Hollingworth S, et al. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. Expert Opin Drug Saf 2019;18(12):1149-1160. https://doi.org/10.1080/1 4740338.2019.1674809
44. Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). Am J Psychiatry 2011;168(9):947-956. https://doi. org/10.1176/appi.ajp.2011.10111609
45. ASOI Adult Obesity Clinical Practice Guideline adaptation (ASOI version 1, 2022) by: O’Dwyer S, Allen S, Fitzgerald I, Moore S, Yoder R. Chapter adapted from: Taylor VH, Sockalingam S, Hawa R, Hahn M. https://asoi.info/guidelines/mentalhealth/ (accessed 21 October 2024).
46. Siskind D, Gallagher E, Winckel K, et al. Does switching antipsychotics ameliorate weight gain in patients with severe mental illness? A systematic review and meta-analysis. Schizophr Bull 2021;47(4):948-958. https://doi.org/10.1093/schbul/sbaa191
47. Speyer H, Westergaard C, Albert N, et al. Reversibility of antipsychotic-induced weight gain: A systematic review and meta-analysis. Front Endocrinol (Lausanne) 2021;12:577919. https://doi. org/10.3389/fendo.2021.577919
48. Vancampfort D, Firth J, Correll CU, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: A meta-review of meta-analyses of randomized controlled trials. Focus (Madison) 2021;19(1):116-128. https://doi. org/10.1176/appi.focus.19103
49. Choi Y-J. Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: A systematic review and meta‐analysis. ScientificWorldJournal 2015;2015:970730. https://doi.org/10.1155/2015/970730
50. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic- related weight gain and metabolic abnormalities: A systematic review and meta-analysis. Neuropsychopharmacology 2010;35(7):1520-1530. https://doi.org/10.1038/npp.2010.21
51. Fiedorowicz JG, Miller DD, Bishop JR, Calarge CA, Ellingrod VL. Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. Curr Psychiatry Rev 2012;8(1):25-36. https://doi.org/10.2174/157340012798994867
52. De Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: A systematic review and meta- analysis. BMC Psychiatry 2016;16(1):341. https://doi.org/10.1186/s12888-016-1049-5
53. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second-generation antipsychotics in the treatment of schizophrenia: A systematic review and meta- analysis. Schizophr Res 2010;123(2-3):225-233. https://doi.org/10.1016/j.schres.2010.07.012
54. Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL. Weight change by baseline BMI from three-year observational data: Findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database. J Psychopharmacol 2013;27(4):358-365. https://doi.org/10.1177/0269881112473789
55. Fitzgerald I, O’Connell J, Keating D, Hynes C, McWilliams S, Crowley EK. Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: Development of the first evidence-based guideline using GRADE methodology. BMJ Ment Health 2022;25(1):15-22. https:// doi.org/10.1136/ebmental-2021-300291
56. Siskind D, Hahn M, Correll CU, et al. Glucagon-like peptide-1 receptor agonists for antipsychotic- associated cardio-metabolic risk factors: A systematic review and individual participant data meta- analysis. Diabetes Obes Metab 2019;21(2):293-302. https://doi.org/10.1111/dom.13522
57. Ishøy PL, Knop FK, Broberg BV, et al. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial. Diabetes Obes Metab 2017;19(2):162-171. https://doi.org/10.1111/dom.12795
58. Siskind DJ, Russell AW, Gamble C, et al. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX). Diabetes Obes Metab 2018;20(4):1050-1055. https://doi.org/10.1111/dom.13167
59. O’Neil PM, Aroda VR, Astrup A, et al. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab 2017;19(11):1529-1536. https://doi.org/10.1111/dom.12963
60. Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med 2025;31(3):951-962. https://doi.org/10.1038/s41591-024-03412-w
61. Lyu X, Du J, Zhan G, et al. Naltrexone and bupropion combination treatment for smoking cessation and weight loss in patients with schizophrenia. Front Pharmacol 2018;9:181. https://doi.org/10.3389/ fphar.2018.00181
62. Taveira TH, Wu WC, Tschibelu E, et al. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: A randomized double-blind placebo-controlled pilot study. J Psychopharmacol 2014;28(4):395-400. https://doi.org/10.1177/0269881113509904
63. Guerdjikova AI, Walsh B, Shan K, Halseth AE, Dunayevich E, McElroy SL. Concurrent improvement in both binge eating and depressive symptoms with naltrexone/bupropion therapy in overweight or obese subjects with major depressive disorder in an open-label, uncontrolled study. Adv Ther 2017;34(10):2307-2315. https://doi.org/10.1007/s12325-017-0613-9
64. Joffe G, Takala P, Tchoukhine E, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: A 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69(5):706-711. https://doi.org/10.4088/jcp.v69n0503
65. Goh KK, Chen CH, Lu ML. Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: Meta-analysis of randomised controlled trials. Int J Psychiatry Clin Pract 2019;23(1):14- 32. https://doi.org/10.1080/13651501.2018.1449864
66. Lee S, Sziklas V, Andermann F, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 2003;44(3):339-347. htpps://doi.org/10.1046/j.1528-1157.2003.27402.x 67. Van Ameringen M, Mancini C, Pipe B, Campbell M, Oakman J. Topiramate treatment for SSRI- induced weight gain in anxiety disorders. J Clin Psychiatry 2002;63(11):981-984. https://doi.
org/10.4088/jcp.v63n1104
68. Tham M, Chong TW, Jenkins ZM, Castle DJ. The use of anti-obesity medications in people with mental illness as an adjunct to lifestyle interventions – effectiveness, tolerability and impact on eating behaviours: A 52-week observational study. Obes Res Clin Pract 2021;15(1):49-57. https://doi. org/10.1016/j.orcp.2020.11.002
69. iNova Pharmaceuticals. Duromine professional information. 2020. https://inovapharma.co.za/brands- and-products/professional-information/ (accessed 23 December 2024).
70. Kishi T, Iwata N. Efficacy and tolerability of histamine-2 receptor antagonist adjunction of antipsychotic treatment in schizophrenia: A meta-analysis of randomised placebo-controlled trials. Pharmacopsychiatry 2015;48(1):30-36. https://doi.org/10.1055/s-0034-1390478
71. Pagoto S, Schneider KL, Whited MC, et al. Randomized controlled trial of behavioral treatment for comorbid obesity and depression in women: The Be Active trial. Int J Obes (Lond) 2013;37(11):1427- 1434. https://doi.org/10.1038/ijo.2013.25
72. Linde JA, Simon GE, Ludman EJ, et al. A randomized controlled trial of behavioral weight loss treatment versus combined weight loss/depression treatment among women with comorbid obesity and depression. Ann Behav Med 2011;41(1):119-130. https://doi.org/10.1007/s12160-010-9232-2
73. Firth J, Cotter J, Elliott R, French P, Yung AR. A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med 2015;45(7):1343-1361. https://doi.org/10.1017/ S0033291714003110
74. Pearsall R, Smith DJ, Pelosi A, Geddes J. Exercise therapy in adults with serious mental illness: A systematic review and meta-analysis. BMC Psychiatry 2014;14:117. https://doi.org/10.1186/1471- 244X-14-117
75. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. Schizophr Res 2012;140(1-3):159-168. https://doi. org/10.1016/j.schres.2012.03.017
76. Bonfioli E, Berti L, Goss C, Muraro F, Burti L. Health promotion lifestyle interventions for weight management in psychosis: A systematic review and meta-analysis of randomised controlled trials. BMC Psychiatry 2012;12:78. https://doi.org/10.1186/1471-244X-12-78
77. Gierisch JM, Nieuwsma JA, Bradford DW, et al. Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: A systematic review and meta-analysis. J Clin Psychiatry 2014;75(5):e424-e440. https://doi.org/10.4088/JCP.13r08558
78. Naslund JA, Whiteman KL, McHugo GJ, Aschbrenner KA, Marsch LA, Bartels SJ. Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: A systematic review and meta-analysis. Gen Hosp Psychiatry 2017;47:83-102. https://doi.org/10.1016/j. genhosppsych.2017.04.003
79. Bruins J, Jörg F, Bruggeman R, Slooff C, Corpeleijn E, Pijnenborg M. The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: A meta-analysis. PLoS ONE 2014;9(12):e112276. https://doi. org/10.1371/journal.pone.0112276
80. Speyer H, Jakobsen AS, Westergaard C, et al. Lifestyle interventions for weight management in people with serious mental illness: A systematic review with meta-analysis, trial sequential analysis, and meta-regression analysis exploring the mediators and moderators of treatment effects. Psychother Psychosom 2019;88(6):350-386. https://doi.org/10.1159/000502293
81. Holt RIG, Gossage-Worrall R, Hind D, et al. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): Randomised controlled trial. Br J Psychiatry 2019;214(2):63-73. https://doi.org/10.1192/bjp.2018.167
82. Lingvay I, Cohen RV, le Roux CW, Sumithran P. Obesity in adults. Lancet 2024;404(10456):972-987.
https://doi.org/10.1016/S0140-6736(24)01210-8
83. Firth J, Solmi M, Wootton RE, et al. A meta‐review of ‘lifestyle psychiatry’: The role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatry 2020;19(3):360-380. https://doi.org/10.1002/wps.20773
84. Peat CM, Berkman ND, Lohr KN, et al. Comparative effectiveness of treatments for binge-eating disorder: Systematic review and network meta-analysis. Eur Eat Disord Rev 2017;25(5):317-328. https://doi.org/10.1002/erv.2517
85. Hilbert A, Petroff D, Herpertz S, et al. Meta-analysis of the efficacy of psychological and medical treatments for binge-eating disorder. J Consult Clin Psychol 2019;87(1):91-105. https://doi. org/10.1037/ccp0000358
86. National Institute for Health and Care Excellence (NICE). Eating disorders: Recognition and treatment. London: NICE, last updated 16 December 2020. https://www.nice.org.uk/guidance/ng69/ resources/eating-disorders-recognition-and-treatment-pdf-1837582159813 (accessed 19 February 2025).
87. Mitchell JE, Selzer F, Kalarchian MA, et al. Psychopathology before surgery in the Longitudinal Assessment of Bariatric Surgery-3 (LABS-3) psychosocial study. Surg Obes Relat Dis 2012;8(5):533- 541. https://doi.org/10.1016/j.soard.2012.07.001
88. Ariel AH, Perri MG. Effect of dose of behavioral treatment for obesity on binge eating severity. Eat Behav 2016;22:55-61. https://doi.org/10.1016/j.eatbeh.2016.03.032
89. Schulte EM, Avena NM, Gearhardt AN. Which foods may be addictive? The roles of processing, fat content, and glycemic load. PLoS ONE 2015;10(2):e0117959. https://doi.org/10.1371/journal. pone.0117959
90. Curtis C, Davis C. A qualitative study of binge eating and obesity from an addiction perspective. Eat Disord 2014;22(1):19-32. https://doi.org/10.1080/10640266.2014.857515
91. Gilhooly CH, Das SK, Golden JK, et al. Food cravings and energy regulation: The characteristics of craved foods and their relationship with eating behaviors and weight change during 6 months of dietary energy restriction. Int J Obes (Lond) 2007;31(12):1849-1858. https://doi.org/10.1038/sj.ijo.0803672
92. Gearhardt AN, White MA, Masheb RM, Morgan PT, Crosby RD, Grilo CM. An examination of the food addiction construct in obese patients with binge eating disorder. Int J Eat Disord 2012;45(5):657- 663. https://doi.org/10.1002/eat.20957
93. Davis C. A commentary on the associations among ‘food addiction’, binge eating disorder, and obesity: Overlapping conditions with idiosyncratic clinical features. Appetite 2017;115:3-8. https://doi. org/10.1016/j.appet.2016.11.001
94. Gearhardt AN, Hebebrand J. The concept of ‘food addiction’ helps inform the understanding of overeating and obesity: Debate consensus. Am J Clin Nutr 2021;113(2):274-276. https://doi. org/10.1093/ajcn/nqaa345
95. Cassin SE, Buchman DZ, Leung SE, et al. Ethical, stigma, and policy implications of food addiction: A scoping review. Nutrients 2019;11(4):710. https://doi.org/10.3390/nu11040710
96. Muhlhans B, Horbach T, de Zwaan M. Psychiatric disorders in bariatric surgery candidates: A review of the literature and results of a German prebariatric surgery sample. Gen Hosp Psychiatry 2009;31(5):414-421. https://doi.org/10.1016/j.genhosppsych.2009.05.004
97. Taylor VH, Hensel J. Multimorbidity: A review of the complexity of mental health issues in bariatric surgery candidates informed by Canadian data. Can J Diabetes 2017;41(4):448-452. https://doi. org/10.1016/j.jcjd.2017.04.004
98. Dawes AJ, Maggard-Gibbons M, Maher AR, et al. Mental health conditions among patients seeking and undergoing bariatric surgery: A meta-analysis. JAMA 2016;315(2):150-163. https://doi. org/10.1001/jama.2015.18118
99. Van der Merwe M-T, Fetter G, Naidoo S, et al. Baseline patient profiling and three-year outcome data after metabolic surgery at a South African centre of excellence. J Endocr Metab Diabetes S Afr 2015;20(3):16-27. https://doi.org/10.1080/16089677.2015.1085700
100. Kruger-Steyn WM, Lubbe J, Louw K-A, Asmal L. Depressive symptoms and quality of life prior to metabolic surgery in Cape Town, South Africa. S Afr J Psychiatry 2022;28:1783. https://doi. org/10.4102/sajpsychiatry.v28i0.1783
101. Herman AA, Stein DJ, Seedat S, Heeringa SG, Moomal H, Williams DR. The South African Stress and Health (SASH) study: 12-month and lifetime prevalence of common mental disorders. S Afr Med J 2009;99(5 Pt 2):339-344.
102. Kalarchian MA, King WC, Devlin MJ, et al. Psychiatric disorders and weight change in a prospective study of bariatric surgery patients: A 3-year follow-up. Psychosom Med 2016;78(3):373-381. https:// doi.org/10.1097/PSY.0000000000000277
103. Thiara G, Cigliobianco M, Muravsky A, et al. Evidence for neurocognitive improvement after bariatric surgery: A systematic review. Psychosomatics 2017;58(3):217-227. https://doi.org/10.1016/j. psym.2017.02.004
104. Nasirzadeh Y, Kantarovich K, Wnuk S, et al. Binge eating, loss of control over eating, emotional eating, and night eating after bariatric surgery: Results from the Toronto Bari-PSYCH cohort study. Obes Surg 2018;28(7):2032-2039. https://doi.org/10.1007/s11695-018-3137-8
105. Bhatti JA, Nathens AB, Thiruchelvam D, Grantcharov T, Goldstein BI, Redelmeier DA. Self-harm emergencies after bariatric surgery: A population-based cohort study. JAMA Surg 2016;151(3):226-232. https://doi.org/10.1001/jamasurg.2015.3414
106. Peterhansel C, Petroff D, Klinitzke G, Kersting A, Wagner B. Risk of completed suicide after bariatric surgery: A systematic review. Obes Rev 2013;14(5):369-382. https://doi.org/10.1111/obr.12014
107. Lim RBC, Zhang MWB, Ho RCM. Prevalence of all-cause mortality and suicide among bariatric surgery cohorts: A meta-analysis. Int J Environ Res Public Health 2018;15(7):1519. https://doi.org/10.3390/ ijerph15071519
108. Li L, Wu LT. Substance use after bariatric surgery: A review. J Psychiatr Res 2016;76:16-29. https://doi. org/10.1016/j.jpsychires.2016.01.009
109. King WC, Chen JY, Mitchell JE, et al. Prevalence of alcohol use disorders before and after bariatric surgery. JAMA 2012;307(23):2516-2525. https://doi.org/10.1001/jama.2012.6147
110. Mitchell JE, Steffen K, Engel S, et al. Addictive disorders after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2015;11(4):897-905. https://doi.org/10.1016/j.soard.2014.10.026
111. King WC, Chen JY, Courcoulas AP, et al. Alcohol and other substance use after bariatric surgery: Prospective evidence from a U.S. multicenter cohort study. Surg Obes Relat Dis 2017;13(8):1392-1402. https://doi.org/10.1016/j.soard.2017.03.021
112. Woodard GA, Downey J, Hernandez-Boussard T, Morton JM. Impaired alcohol metabolism after gastric bypass surgery: A case-crossover trial. J Am Coll Surg 2011;212(2):209-214. https://doi.org/10.1016/j. jamcollsurg.2010.09.020
113. Raebel MA, Newcomer SR, Bayliss EA, et al. Chronic opioid use emerging after bariatric surgery. Pharmacoepidemiol Drug Saf 2014;23(12):1247-1257. https://doi.org/10.1002/pds.3625
114. Raebel MA, Newcomer SR, Reifler LM, et al. Chronic use of opioid medications before and after bariatric surgery. JAMA 2013;310(13):1369-1376. https://doi.org/10.1001/jama.2013.278344
115. Wimmelmann CL, Dela F, Mortensen EL. Psychological predictors of weight loss after bariatric surgery: A review of recent research. Obes Res Clin Pract 2014;8(4):e299-e313. https://doi.org/10.1016/j. orcp.2013.09.003
116. Sheets CS, Peat CM, Berg KC, et al. Post-operative psychosocial predictors of outcome in bariatric surgery. Obes Surg 2015;25(2):330-345. https://doi.org/10.1007/s11695-014-1490-9
117. De Zwaan M, Enderle J, Wagner S, et al. Anxiety and depression in bariatric surgery patients: A prospective, follow-up study using structured clinical interviews. J Affect Disord 2011;133(1-2):61-68. https://doi.org/10.1016/j.jad.2011.03.025
118. Sockalingam S, Cassin SE, Wnuk S, et al. A pilot study on telephone cognitive behavioral therapy for patients six-months post-bariatric surgery. Obes Surg 2017;27(3):670-675. https://doi.org/10.1007/ s11695-016-2322-x
119. Thomson L, Sheehan KA, Meaney C, Wnuk S, Hawa R, Sockalingam S. Prospective study of psychiatric illness as a predictor of weight loss and health related quality of life one year after bariatric surgery. J Psychosom Res 2016;86:7-12. https://doi.org/10.1016/j.jpsychores.2016.04.008
120. Devlin MJ, King WC, Kalarchian MA, et al. Eating pathology and experience and weight loss in a prospective study of bariatric surgery patients: 3-year follow-up. Int J Eat Disord 2016;49(12):1058-1067. https://doi.org/10.1002/eat.22578
121. Sogg S, Lauretti J, West-Smith L. Recommendations for the presurgical psychosocial evaluation of bariatric surgery patients. Surg Obes Relat Dis 2016;12(4):731-749. https://doi.org/10.1016/j.soard.2016.02.008 122. Sogg S, Mori DL. Psychosocial evaluation for bariatric surgery: The Boston Interview and opportunities
for intervention. Obes Surg 2009;19(3):369-377. https://doi.org/10.1007/s11695-008-9676-7
123. Thiara G, Yanofksy R, Abdul-Kader S, et al. Toronto Bariatric Interprofessional Psychosocial Assessment Suitability Scale: Evaluating a new clinical assessment tool for bariatric surgery candidates. Psychosomatics
2016;57(2):165-173. https://doi.org/10.1016/j.psym.2015.12.003
124. Barclay KS, Rushton PW, Forwell SJ. Measurement properties of eating behavior self-assessment tools
in adult bariatric surgery populations: A systematic review. Obes Surg 2015;25(4):720-737. https://doi.
org/10.1007/s11695-015-1593-y
125. Marek RJ, Heinberg LJ, Lavery M, Rish JM, Ashton K. A review of psychological assessment instruments for use in bariatric surgery evaluations. Psychol Assess 2016;28(9):1142-1157. https://doi.org/10.1037/ pas0000286
126. Cassin S, Sockalingam S, Hawa R, et al. Psychometric properties of the Patient Health Questionnaire (PHQ-9) as a depression screening tool for bariatric surgery candidates. Psychosomatics 2013;54(4):352- 358. https://doi.org/10.1016/j.psym.2012.08.010
127. Parker K, O’Brien P, Brennan L. Measurement of disordered eating following bariatric surgery: A systematic review of the literature. Obes Surg 2014;24(6):945-953. https://doi.org/10.1007/s11695-014-1248-4
128. Mitchell JE, King WC, Chen JY, et al. Course of depressive symptoms and treatment in the Longitudinal Assessment of Bariatric Surgery (LABS-2) study. Obesity (Silver Spring) 2014;22(8):1799-1806. https://doi. org/10.1002/oby.20738
129. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev 2010;11(1):41-50. https://doi.org/10.1111/j.1467-789X.2009.00614.x 130. Roerig JL, Steffen K. Psychopharmacology and bariatric surgery. Eur Eat Disord Rev 2015;23(6):463-469.
https://doi.org/10.1002/erv.2396
131. Hamad GG, Helsel JC, Perel JM, et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry 2012;169(3):256-263. https://doi.org/10.1176/appi.ajp.2011.11050719 132. Bingham K, Hawa R, Sockalingam S. SSRI discontinuation syndrome following bariatric surgery: A case report and focused literature review. Psychosomatics 2014;55(6):692-697. https://doi.org/10.1016/j.
psym.2014.07.003
133. Bingham KS, Thoma J, Hawa R, Sockalingam S. Perioperative lithium use in bariatric surgery: A case series and literature review. Psychosomatics 2016;57(6):638-644. https://doi.org/10.1016/j.psym.2016.07.001 134. Bingham KS, Yanofsky R. Psychopharmacology in bariatric surgery patients. In: Sockalingam SHR, ed.
Psychiatric Care in Severe Obesity. Cham, Switzerland: Springer, 2017:313-333.
135. ASOI Adult Obesity Clinical Practice Guideline adaptation (ASOI version 1, 2022) by: O’Dwyer S, Allen S, Fitzgerald I, Moore S, Yoder R. Chapter adapted from: Taylor VH, Sockalingam S, Hawa R, Hahn M.
https://asoi.info/guidelines/mentalhealth/ (accessed 21 October 2024).
136. Ogden J, Hollywood A, Pring C. The impact of psychological support on weight loss post weight loss
surgery: A randomised control trial. Obes Surg 2015;25(3):500-505. https://doi.org/10.1007/s11695-014-
1428-2
137. Stewart F, Avenell A. Behavioural interventions for severe obesity before and/or after bariatric surgery: A systematic review and meta-analysis. Obes Surg 2016;26(6):1203-1214. https://doi.org/10.1007/s11695- 015-1873-6
138. Rudolph A, Hilbert A. Post-operative behavioural management in bariatric surgery: A systematic review and meta-analysis of randomized controlled trials. Obes Rev 2013;14(4):292-302. https://doi. org/10.1111/obr.12013Kalarchian MA, Marcus MD. Psychosocial interventions pre and post bariatric surgery. Eur Eat Disord Rev 2015;23(6):457-462. https://doi.org/10.1002/erv.2392
139. Paul L, van der Heiden C, Hoek HW. Cognitive behavioral therapy and predictors of weight loss in bariatric surgery patients. Curr Opin Psychiatry 2017;30(6):474-479. https://doi.org/10.1097/ YCO.0000000000000359
140. Bradley LE, Forman EM, Kerrigan SG, Butryn M, Herbert JD, Sarwer DB. A pilot study of an acceptance-based behavioral intervention for weight regain after bariatric surgery. Obes Surg 2016;26(10):2433-2441. https://doi.org/10.1007/s11695-016-2125-0
141. Wnuk SM, Du CT, van Exan J, et al. Mindfulness-based eating and awareness training for post- bariatric surgery patients: A feasibility pilot study. Mindfulness 2018;9(3):949-960. https://doi. org/10.1007/s12671-017-0834-7
142. Vidal P, Ramón JM, Goday A, et al. Lack of adherence to follow-up visits after bariatric surgery: Reasons and outcome. Obes Surg 2014;24(2):179-183. https://doi.org/10.1007/s11695-013-1094-9
143. Kim HJ, Madan A, Fenton-Lee D. Does patient compliance with follow-up influence weight loss after
gastric bypass surgery? A systematic review and meta-analysis. Obes Surg 2014;24(4):647-651. https://
doi.org/10.1007/s11695-014-1178-1
144. Goode RW, Ye L, Sereika SM, et al. Socio-demographic, anthropometric, and psychosocial predictors of attrition across behavioral weight-loss trials. Eat Behav 2016;20:27-33. https://doi.org/10.1016/j. eatbeh.2015.11.009
145. Moroshko I, Brennan L, O’Brien P. Predictors of dropout in weight loss interventions: A systematic review of the literature. Obes Rev 2011;12(11):912-934. https://doi.org/10.1111/j.1467- 789X.2011.00915.x
146. Larjani S, Spivak I, Hao Guo M, et al. Preoperative predictors of adherence to multidisciplinary follow- up care postbariatric surgery. Surg Obes Relat Dis 2016;12(2):350-356. https://doi.org/10.1016/j. soard.2015.11.007
147. Sockalingam S, Cassin S, Hawa R, et al. Predictors of post-bariatric surgery appointment attendance: The role of relationship style. Obes Surg 2013;23(12):2026-2032. https://doi.org/10.1007/s11695-013- 1009-9
148. Hood MM, Corsica J, Bradley L, Wilson R, Chirinos DA, Vivo A. Managing severe obesity: Understanding and improving treatment adherence in bariatric surgery. J Behav Med 2016;39(6):1092- 1103. https://doi.org/10.1007/s10865-016-9772-4
149. Aarts MA, Sivapalan N, Nikzad SE, Seroodio K, Sockalingam S, Conn LG. Optimizing bariatric surgery multidisciplinary follow-up: A focus on patient-centered care. Obes Surg 2017;27(3):730-736. https://doi.org/10.1007/s11695-016-2354-2
150. Sunil S, Santiago VA, Gougeon L, et al. Predictors of vitamin adherence after bariatric surgery. Obes Surg 2017;27(2):416-423. https://doi.org/10.1007/s11695-016-2306-x
Downloads
Published
Issue
Section
License
Copyright (c) 2025 K Mawson, E J Barnard, J Lubbe, M Conradie-Smit, W May
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
